CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM054216
Első szerző:Ajzner Éva (laboratóriumi szakorvos)
Cím:Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding / É. Ajzner, I. Balogh, G. Haramura, Z. Boda, K. Kalmár, G. Pfliegler, B. Dahlbäck, L. Muszbek
Dátum:2003
ISSN:1538-7933
Megjegyzések:Development of autoantibody against coagulation factor V (FV) is a rare clinical condition with hemorrhagic complications of varying severity. The aim of this study was to establish the pathomechanism of an acquired FV deficiency and characterize the FV inhibitor responsible for the clinical symptoms. A 78-year-old female was admitted to hospital with severe gastrointestinal bleeding. General clotting tests and determination of clotting factors were performed by standard methods. FV antigen and FV containing immune complexes were measured by ELISA. The FV molecule was investigated by Western blotting and by sequencing the f5 gene. The binding of patient's IgG to FV and activated FV (FVa) was demonstrated in an ELISA system and its effect on the procoagulant activity of FVa was tested in clotting tests and in a chromogenic prothrombinase assay. Localization of the epitope for the antibody was performed by blocking ELISA. FV activity was severely suppressed both in plasma and platelets. FV antigen levels were normal by ELISA using polyclonal anti-FV antibody or monoclonal antibody against the connecting region of FV, but depressed when HV1 monoclonal antibody against the C2 domain in the FV light-chain was used as capture antibody. The FV molecule was found intact. An IgG reacting with both FV and FVa was present in the patient's plasma and its binding to FV was inhibited by HV1 antibody. FV-containing immune complexes were detected in the patient's plasma and platelet lysate. The patient's IgG inhibited the procoagulant function of FVa. An anti-FV IgG was present in the patient's plasma and platelets. The autoantibody reacted with an epitope in the C2 domain of FV light chain and neutralized the procoagulant function of FVa.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of thrombosis and haemostasis. - 1 : 5 (2003), p. 943-949. -
További szerzők:Balogh István (1972-) (molekuláris biológus, genetikus) Haramura Gizella (1957-) (vezető analitikus) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Kalmár Kálmán Pfliegler György (1949-) (belgyógyász, hematológus, labor szakorvos) Dahlbäck, Björn Muszbek László (1942-) (haematológus, kutató orvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM084884
035-os BibID:(WoS)000379164000245
Első szerző:Bereczky Zsuzsanna (orvosi laboratóriumi diagnosztika szakorvos)
Cím:Diagnostic issues in antithrombin, protein C and protein S deficiency in the hungarian population : experience of a large thrombosis laboratory / Bereczky Z., Speker M., Gindele R., Szabo Z., Oláh Z., Pfliegler G., Kerényi A., Boda Z.
Dátum:2016
ISSN:1538-7933 1538-7836
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:Journal of Thrombosis and Haemostasis. - 14 : Suppl. 1 (2016), p. 98. -
További szerzők:Speker Marianna Gindele Réka (1987-) (molekuláris biológus) Szabó Zsuzsa (1990-) (kémikus) Oláh Zsolt (1974-) (belgyógyász) Pfliegler György (1949-) (belgyógyász, hematológus, labor szakorvos) Kerényi Adrienne (1970-) (laboratóriumi szakorvos) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM019249
Első szerző:Gézsi András
Cím:Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza / A. Gézsi, U. Budde, I. Deák, E. Nagy, A. Mohl, Á. Schlammadinger, Z. Boda, T. Masszi, J. E. Sadler, I. Bodó
Dátum:2010
Megjegyzések:von Willebrand disease (VWD) Vicenza is characterized by low plasma von Willebrand factor (VWF) levels, the presence of ultra-large (UL) VWF multimersand less prominent satellite bands on multimer gels, and the heterozygous amino acid substitution R1205H in the VWFgene. The pathogenesis of VWD Vicenza has been elusive.Accelerated clearance is implicated as a cause of low VWF level. Objectives: We addressed the question, whether the presence of ultra-large multimers is a cause, or a result of accelerated VWF clearance, or whether it is an unrelated phenomenon. Patients/methods: We studied the detailed phenotype of three Hungarian patients with VWD Vicenza, expressed the mutant VWFR1205H in 293T cells and developed a mathematical model to simulate VWF synthesis and catabolism. Results: We found that the half-life of VWF after DDAVP was approximately one tenth of that after the administration of Haemate P, a source of exogenous wild-type (WT) VWF (0.81 ? 0.2 vs. 7.25 ? 2.38 h). An analysis of recombinant mutant VWF-R1205H showed that the biosynthesis and multimer structure ofWT and mutant VWF were indistinguishable. A mathematical model of the complex interplay of VWF synthesis, clearance and cleavageshowed that decreasing VWF half-life to one-tenth of normalreproduced all features of VWD Vicenza including low VWFlevel, ultra-large multimers and a decrease of satellite band intensity. Conclusion: We conclude that accelerated clearance alone may explain all features of VWD Vicenza.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
clearance
von Willebrand disease
von Willebrand factor
Megjelenés:Journal of Thrombosis and Haemostasis. - 8 : 6 (2010), p. 1273-1280. -
További szerzők:Budde, U. Deák Ivett Nagy E. Mohl, A. Schlammadinger Ágota (1971-) (belgyógyász, haematológus) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Masszi Tamás Sadler, J. E. Bodó I.
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM063574
035-os BibID:(WoS)000374979000010 (Scopus)84959145645
Első szerző:Gindele Réka (molekuláris biológus)
Cím:Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary : phenotype analysis in a large cohort / R. Gindele, Z. Olah, P. Ilonczai, M. Speker, A. Udvari, A. Selmeczi, G. Pfliegler, E. Marjan, B. Kovacs, Z. Boda, L. Muszbek, Z. Bereczky
Dátum:2016
ISSN:1538-7933
Megjegyzések:Background: Antithrombin (AT) is a key regulatorof the coagulation. In type II deficiency, the heparinbinding-site defect (type II HBS) is considered to be relativelylow thrombosis risk. Objectives: Our aims were tosearch for SERPINC1 mutation(s) and to describe the clinicaland laboratory phenotype of a large number of ATBudapest3 (ATBp3, p.Leu131Phe) carriers and confirm thepresence of a founder effect. Patients/Methods: AT-deficientpatients were recruited and carriers of ATBp3,n = 102 (63 families) were selected. To investigate the foundereffect, eight intragenic single nucleotide polymorphisms,a 50-length dimorphism, and five microsatellitemarkers were detected. Clinical and laboratory data of thepatients were collected and analyzed. Results: In AT deficiency,16 different causative mutations were found, andthe great majority of patients were of type II HBS subtype.Most of them (n = 102/118, 86.5%) carried the ATBp3mutation. The ATBp3 mutant allele was associated withone single haplotype, while different haplotypes weredetected in the case of normal allele. The anti?factor Xa?based AT activity assay that we used could detect allATBp3 patients with high sensitivity in our cohort. ATBp3homozygosity (n = 26) was associated with thrombosis at ayoung age and conferred a high thrombotic risk. Half ofthe heterozygotes (n = 41/76, 53.9%) also had venous and/or arterial thrombosis, and pregnancy complications werealso recorded. Conclusion: In Hungary, the founder mutation,ATBp3, is the most common AT deficiency. Ourstudy is the first in which the clinical characterization ofATBp3 mutation was executed in a large population.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
antithrombin III deficiency
antithrombin III
thrombophilia
founder effect
venous thromboembolism
Megjelenés:Journal Of Thrombosis And Haemostasis. - 14 : 4 (2016), p. 704-715. -
További szerzők:Oláh Zoltán Ilonczai Péter (1977-) (orvos, belgyógyász, haematológus szakorvos) Speker Marianna Udvari Á. Selmeczi Anna (1982-) (orvos) Pfliegler György (1949-) (belgyógyász, hematológus, labor szakorvos) Marján Erzsébet Kovács Bettina (1975-) (orvos) Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Muszbek László (1942-) (haematológus, kutató orvos) Bereczky Zsuzsanna (1974-) (orvosi laboratóriumi diagnosztika szakorvos)
Pályázati támogatás:PD101120
OTKA
K116228
OTKA
TÁMOP-4.2.2.A-11/1/KONV-2012-0045
TÁMOP
Trombózis Kutató Központ Kutatócsoport
11003
MTA
TKI227
MTA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM034335
Első szerző:Mohl, A.
Cím:Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population / Mohl A., Boda Z., Jager R., Losonczy H., Marosi A., Masszi T., Nagy E., Nemes L., Obser T., Oyen F., Radványi G., Schlammadinger Á., Szélessy Zs., Várkonyi A., Vezendy K., Vilimi B., Schneppenheim R., Bodó I.
Dátum:2011
ISSN:1538-7933
Megjegyzések:BACKGROUND: Type 3 von Willebrand disease (VWD) is an autosomal recessive bleeding disorder, characterized by virtually undetectable plasma von Willebrand factor (VWF) and consequently reduced plasma factor VIII levels. Genetic mutations responsible for type 3 VWD are very heterogeneous, scattered throughout the VWF gene and show high variability among different populations. METHODS: Twenty-five severe VWD patients were studied by direct sequencing of the 51 coding exons of the VWF gene. The total number of VWD type 3 families in Hungary is 24, of which 23 were investigated. RESULTS: Fifteen novel mutations were identified in 31 alleles, five being nonsense mutations (p.Q1238X, p.Q1898X, p.Q1931X, p.S2505X and p.S2568X), four small deletions and insertions resulting in frame shifts (c.1992insC, c.3622delT, c.5315insGA and c.7333delG), one a large partial deletion (delExon1-3) of the 5'-region, four candidate missense mutations (p.C35R, p.R81G, p.C295S, p.C623T) and one a candidate splice site mutation (c.1730-10C>A). Six previously described mutations were detected in 17 alleles, including the repeatedly found c.2435delC, p.R1659X and p.R1853X. Only one patient developed alloantibodies to VWF, carrying a homozygous c.3622delT. CONCLUSION: We report the genetic background of the entire Hungarian type 3 VWD population. A large novel deletion, most probably due to a founder effect, seems to be unique to Hungarian type 3 VWD patients with high allele frequency. In contrast to previous reports, none of the five patients homozygous for the large partial deletion developed inhibitors to VWF. This discrepancy raises the possibility of selection bias in some of the reports.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
genetic defect
type 3
von Willebrand disease
Megjelenés:Journal Of Thrombosis And Haemostasis. - 9 : 5 (2011), p. 945-952. -
További szerzők:Boda Zoltán (1947-) (belgyógyász, haematologus, klinikai onkológus) Jáger Rita Losonczy Hajna Marosi A. Masszi Tamás Nagy E. Nemes László Obser, T. Oyen, F. Radványi Gáspár Schlammadinger Ágota (1971-) (belgyógyász, haematológus) Szélessy Zs. Várkonyi Ágnes Vezendy K. Vilimi B. Schneppenheim, Reinhard Bodó I.
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1